Security assessments indicated that gastrointestinal adverse occasions, generally nausea and diarrhea, had been dose-dependent but generally moderate and transient. These conclusions proven the therapeutic window and informed dose range for subsequent Section 3 trials.This smaller sized dimensions makes it possible for orforglipron to survive diges